Bibliografía del artículo
1- Adams KF, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR,Abraham WT, Berkowitz RL, Galvao M, Horton DP. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149:209-216.
2- . Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A,Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, et al. The EuroHeart Failure Survey programme: a survey on the quality of careamong patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003; 24:442– 463.
3. Filippatos G, Leche C, Sunga R, Tsoukas A, Anthopoulos P, Joshi I, Bifero A, Pick R, Uhal BD. Expression of FAS adjacent to fibrotic foci in the failing human heart is not associated with increased apoptosis. Am J Physiol 1999; 277:H445–H451.
4- Kono T, Sabbah HN, Rosman H, Alam M, Jafri S, Goldstein S. Left ventricular shape is the primary determinant of functional mitral regurgitation in heart failure. J Am Coll Cardiol 992;20:
1594 –1598.
5. Sabbah HN, Rosman H, Kono T, Alam M, Khaja F, Goldstein S. On the mechanism of functional mitral regurgitation. Am J Cardiol 1993; 72:1074 –1076.
6. Grossman E, Oren S, Messerli FH. Left ventricular filling and stress response pattern in essential hypertension. Am J Med 1991;91:502–506.
7. Grossman W. Diastolic dysfunction and congestive heart failure. Circulation1990;81(suppl):
III1–III7.
8- Perna ER, Macin SM, Cimbaro Canella JP, et al. Minor myocardial damage detected by troponin T is a powerful predictor of long-term prognosis in patients with acute decompensated heart failure. Int J Cardiol 2005;99:253- 61
9- Gheorgheade M, De Luca L, Fonarow G. Pathophysiologic Targets in the Early Phase of Acute Heart Failure Syndromes. Am J Cardiol 2005; 96 [suppl]:11G–17G)
10- Katz AM. A new inotropic drug: its promise and caution. N Engl J Med.1978;299:1409-1410
11- Ganda A, Onat D, Demmer R,et al. Venous congestion and Endothelial Cell Activation in Acute Decompensated Heart Failure.Curr Heart Fail Rep 2010; 7:66-74
12-Colombo PC, Onat D, Sabbah HN.: Acute heart failure as “acute endothelitis” – Interaction of fluid overload and endothelial dysfunction. Eur J Heart Fail 2008;10:170-75.
13- Yu CM, Wang L, Chau E, et al. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization.
Circulation 2005,112: 841-848.
14- Chaudhry S, Wang Y, Concato J, et al. Patterns of weight change preceding hospitalization for heart failure. Circulation 2007,116:1549-1554
15- Gheorghiade M, Filippatos G, De Luca L, et al. Congestion in Acute Heart Failure Syndromes:An Essential Target of Evaluation and Treatment . Am J Med 2006, 119 (12A), S3–S10
16-Lauga A, D’Hortensio A.Guia de Monitoreo Hemodinamico. Monitoreo de las presiones de la arteria Pulmonar. parte I. Insuficiencia Cardiaca. Revista Especializada en Insuficiencia Cardiaca, cardiometabolismo e hipertensión pulmonar. 2007; II, Nro 1: 5-12
17-Forrester JS, Diamond GA, Swan HJ. Correlative classification of clinical and hemodynamic function after acute myocardial infarction. Am J Cardiol 1977; 39:137-45
18- Nohria A, Tsang SW, Fang JC, Lewis EF, Jarcho JA, Mudge GH, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 2003;41:1797-804.
19-.Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC; Adhere Scientific Advisory Committee and Investigators. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 2006;47;1:76-84.
20- De la Serna F, Lobo Marquez L. Insuficiencia Cardiaca Cronica. De la Serna F.
Sindromes agudos de IC. Sindrome cardiorrenal. Anemia. 2011,12: 359- 386
(online www.fac.org.ar.)
21- Stevenson LW.; Perloff J. The limited Reability of Physical Signs for Estimating Hemodynamics in Chronic Heart Failure. JAMA 1989; 261: 884-888
22-Gheorghiade M, Abraham WT, Albert NM, et al. OPTIMIZE-HF Investigators and Coordinators Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006; 296:2217–2226.
23-Chakko S, Woska D, Martinez H, et al. Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care. Am J Med 90:353–359
24-Butman SM, Ewy GA, Standen JR, et al .Bedside cardiovascular examination in patients with severe chronic heart failure: importance of rest or inducible jugular venous distension. J Am Coll Cardiol 1993; 22:968–974
25-Campbell P, Drazner M, Kato M. Mismatch of Right- and Left- Sided Filling Pressures in Chronic Heart Failure. J Cardiac Fail 2011;17:561-568.
26- Maisel A, Mueller C, Adams K, et al. Review. State of the art: Using natriuretic peptide levels in clinical practice. Eur J of Heart Fail 2008; (10),9:824 – 839
27- Temporelli P, Scapellato F, Eleuteri E, et al. Doppler Echocardiography in Advanced Systolic Heart Failure. A Noninvasive Alternative to Swan-Ganz Catheter. Circ Heart Fail. 2010;3:387-394.
28- Kirkpatrick J, Mani A, Vannan M, et al. Echocardiography in Heart Failure.Applications, Utility, and New Horizons.J Am Coll Cardiol 2007;50:381–96
29- Lucas C, Johnson W, Hamilton MA, et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J. 2000;140:840-847.
30-Gheorghiade M, Gattis WA, O’Connor CM, et al. for Acute and Chronic Therapeutic Impact of a Vasopression Antagonist in Congestive Heart Failure (ACTIVE in CHF) Investigators. Effects of Tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.JAMA.2004;209:1963-1971
31- Drazner MH, Rame JE, Stevenson LW, et al. Prognostic importance of elevated jugular venous pressure and third heart sound in patients with heart failure. N Eng J Med.2001;
345:574-581.
32-Gheorghiade M, Follath F, Ponikowski P, et al. Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J of Heart Fail 2010; 12: 423–433.
33-Lobo Marquez, L. El “Continuum” de la Insuficiencia Cardíaca. Insuf Card 2010; (Vol 5)
1:25-31.
34-Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007; 297:1332–1343.
35- Lobo Marquez,L. Monitoreo Hemodinamico. Piu Avanti. Rev Insuf Cardíaca 2007; (Vol 2) 4:149-152
36. Stevenson LW; Tillisch Jan H. Maintenance of cardiac output with normal filling pressures in patients with heart failure.Circulation1986;74;6:1303-1308.
37. Steimle A, Stevenson LW, Chelimsky-Fallick C. Sustained Hemodynamic Efficacy of Therapy Tailored to Reduce Filling Pressures in Survivors with Advanced Heart Failure. Circulation 1997;96:1165-1172.
38. Hamilton M, Stevenson LW, Child J, Moriguchi J, Walden J. Sustained Reduction in Valvular Regurgitation and Atrial Volumes with tailored
vasodilator therapy in Advanced Congestive Heart Secondary to Dilated (Ischemic or Idiopathic) Cardiomyopathy. Am J Cardiol 1991;67:259-263.
39. Cohn J, Goldstein S, Greenberg B, Lorell B. Vesnarinone Trial Investigators. A dose dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med 1998;339:1810-1816.
40-. Stevenson LW, Couper G, Natterson B, Fonarow G. Target Heart Failure Populations for Newer Therapies .Circulation 1995;92 (supl II):II174-II181.
41-. Stevenson LW. Tailored therapy to hemodynamic goals for advanced heart failure. Eur J Heart Fail 1999;1:251-257.
42- The ESCAPE Investigators and ESCAPE Study Coordinators. Evaluation study of congestive heart failure and pulmonary artery catheterization: the ESCAPE trial. JAMA 2005;294:1625-1633.
43- Lobo Márquez,L. Monitoreo Hemodinamico. Piu Avanti. Rev. Insuf. Cardíaca 2007; (Vol 2) 4:149-152.
44-Rozenman Y.; Schwartz R.; Shah H. Wireless Acoustic Communication with a Miniature Pressure Sensor in Pulmonary Artery for Disease Surveillance and Therapy with Congestive Heart Failure. JACC 2007;49,No 7: 784-9
45-Bourge R, Abraham W, Philip B, et al on behalf of the COMPASS-HF Study Group. Randomized Controlled Trial of an Implantable Continuous Hemodynamic Monitor in Patients With Advanced H eart Failure The COMPASS-HF Study. J Am Coll Cardiol 2008;51: 1073–9.
46-Piccini J,Hranitzky P. Diagnostic monitoring strategies in heart failure management. Am Heart J 2007; 153:S12-7
47-Whellan D, Ousdigian K, Al-Khatib S, et al for the PARTNERS Study Investigators Combined Heart Failure Device Diagnostics Identify Patients at Higher Risk of Subsequent Heart Failure Hospitalizations Results From PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure) Study. J Am Coll. Cardiol 2010;55:1803–10.
48-Wilson Tang W. Collaboration Among General Cardiologists, Heart Failure Specialists, and Electrophysiologists: What Are the Barriers? Am J Cardiol 2007;99 [suppl]:41G–44G
49-Weintraub A, Gregory D,. Patel A, et al. A Multicenter Randomized Controlled Evaluation of Automated Home Monitoring and Telephonic Disease Management in Patients Recently Hospitalized for Congestive Heart Failure: The SPAN-CHF II Trial. J Cardiac Fail 2010;16:285 – 292.
50-Klersy C, De Silvestri A, Gabutti G, et al. A Meta-Analysis of Remote Monitoring of Heart Failure Patients. J Am Coll Cardiol 2009;54:1683–94